// App-Quantinova.ai

P125 : Long-term efficacy of baricitinib in patients with rheumatoid arthritis who have had inadequate response to csDMARDs: results from RA-BEYOND up to 7 years of treatment

Researchers

Presenter

  • Roberto Caporali

Principal Investigators

  • Daniel Aletaha

  • Raimon Sanmarti

  • Tsutomu Takeuchi

  • Daojun Mo

  • Ewa Haladyj

  • Liliana Zaremba-Pechmann

  • Peter C Taylor

Medical Centers

  • Department of OB/GYN, Division of Senology, Medical University of Vienna, Vienna, Austria

  • Rheumatology Department, Hospital Clínic de Barcelona and IDIBAPS, Barcelona, Spain

  • Dept. of Clinical Sciences & Community Health, Research Center for Adult and Pediatric Rheumatic Diseases, Università degli Studi di Milano, Montu Beccaria, Italy

  • Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom

  • Division of Rheumatology, Department of Internal Medicine, KEIO UNIVERSITY SCHOOL OF MEDICINE, Tokyo, Japan

Locations

  • Austria

  • Germany

  • United States

  • United Kingdom

  • Spain

  • Japan

  • Italy

Companies

  • EMB Statistical Solu

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Rheumatoid arthritis

Biomarkers

  • N/A

Drug/Treatment

  • Baricitinib

  • Adalimumab

  • BARI

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved